

## ABBREVIATED CURRICULUM VITAE

### PERSONAL INFORMATION

<b>First Name:</b>	DIMITRIOS
<b>Last Name:</b>	TZIAKAS
<b>Year of Birth:</b>	1966

### HOSPITAL ADDRESS (Current Position)

<b>Hospital:</b>	UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS		
<b>Clinic /Department:</b>	CARDIOLOGY CLINIC		
<b>Profession</b>	PROFESSOR OF CARDIOLOGY		
<b>Professional License Number</b>	2803/16-10-85 Protocol No: 4614		
<b>Address:</b>	DRAGANA REGION		
<b>Postal Code:</b>	68100		
<b>City:</b>	ALEXANDROUPOLIS		
<b>Country:</b>	GREECE		
<b>Telephone Number:</b>	+302551353205	<b>Fax Number:</b>	+302551353245
<b>E-mail Address:</b>	dtziakas@med.duth.gr		

### ACADEMIC QUALIFICATIONS

<b>Degree and / or Certification</b>	<b>Institution</b>	<b>Year of Completion</b>
MD with Honours	Iasi Medical School, Iasi Medical University - GT Popa, Iasi, Romania	1991

### PROFESSIONAL EXPERIENCE

<b>Position held</b>	<b>Name of Department / Institution</b>	<b>Start Date – End Date</b>
Professor in Medicine (Cardiology),	Medical School, Democritus University of Thrace, Alexandroupolis, Evros, Greece	2015-Today
Associate Professor in Cardiology	Medical School, Democritus University of Thrace, Alexandroupolis, Evros, Greece	May 2011 to 2015
Assistant Professor in Cardiology	Medical School, Democritus University of Thrace, Alexandroupolis, Evros, Greece	June 2005 to May 2012
Lecturer in Cardiology	Medical School, Democritus University of Thrace, Alexandroupolis, Evros, Greece	April 2001 to June 2005
Senior Registrar	Medical School, Democritus University of Thrace, Alexandroupolis, Evros, Greece	July 2000 to April 2001

### PROFESSIONAL SOCIETY MEMBERSHIPS

Member of the Hellenic Cardiology Society
Fellow of the European Society of Cardiology (FESC)
Fellow of the American Heart Association (FAHA)
Fellow of the American College of Cardiology (FACC)
Fellow of the American College of Chest Physicians (FCCP)
Member of the European Society of Atherosclerosis.(EAS)
Member of the Working Group on Acute Cardiac Care of the European Society of Cardiology
Member of the Working Group on Pathogenesis of Atherosclerosis of the European Society of Cardiology
Member of the European Board for the Specialty of Cardiology(EBSC)
Governor of Greece of the International Society of Cardiovascular Pharmacotherapy
Fellow of the Society of Cardiovascular Angiography and Interventions

### FOREIGN LANGUAGES

<b>Language</b>	<b>Fluency / Degree</b>
-----------------	-------------------------

English	Fluent
Greek	Native

### GOOD CLINICAL PRACTICE (GCP)

<b>Duration:</b>	2 years
<b>Title / Content:</b>	Investigator Site Personnel ICH GCP Training Certificate
<b>Provider:</b>	The Global Health network
<b>Training Type:</b>	<b>Physically Present:</b> <input type="checkbox"/> <b>Online training:</b> X
<b>Date of Training Certificate:</b>	04OCT2022

### ADDITIONAL TRAINING

Completion Date	Title / Content:

### MOST CURRENT CLINICAL TRIAL EXPERIENCE

Study Name or Code	Participation Period (total in years)	Role in the study (Principal Investigator or Sub-Investigator or Study Coordinator or Other, specify)	Therapeutic Area:	Clinical Phase (Phase I, II, III, IV)	Study Status (In Progress or Closed)
SERELAXIN		National Leader	Acute Heart Failure	III	Closed
REDUAL PCI		Principal Investigator	NVAf + PCI ( Stent)	III	Closed
AFFILIATE		Sub- Investigator	Pulm. Art. Hyper.	III	Closed
FOURIER		Principal Investigator	Cardiovas. Disease	III	Closed
LATITUDE-TIMI 60		National Leader	Acute Cor. Syndr.	III	Closed
2013-CLOBES-EL-14		Principal Investigator	Cor. artery disease	III	Closed
PEITHO		Sub- Investigator	Pulmonary Embol.	III	Closed
SIGNIFY		Principal Investigator	stable cor.art. dis.	III	Closed
STABILITY		Principal Investigator	Chr. Cor. Heart Dis.	III	Closed
VICTORIA		National Leader	Cardiovas. Disease	III	Closed
PARADISE-MI		Principal Investigator	Cardiovas. Disease	III	closed
GALACTIC-HF		Principal Investigator	Cardiovas. Disease	III	closed
AEGIS- II CSL112_3001		Principal Investigator	Cardiovas. Disease	III	In progress
FINEARTS- HF		Principal Investigator	Cardiovas. Disease	III	In progress
ZEUS		Principal Investigator	Cardiovas. Disease	III	In progress
VICTOR		Principal Investigator	Cardiovas. Disease	III	In progress
LANDMARK		Principal Investigator	Diabetes mellitus	IV	In progress
RETRACE		Principal Investigator	Cardiovas. Disease	IV	In progress

### MOST RECENT PUBLICATIONS

Publication Date	Title / Content:
N Engl J Med. 2014 Sep 18;371(12):1091-9	Ivabradine in stable coronary artery disease without clinical heart failure.
Clin Chim Acta. 2014 Jul 5. pii: S0009-8981(14)00286-1. doi: 10.1016/j.cca.2014.06.028.	Biomarkers of the extracellular matrix and of collagen fragments.
Hellenic J Cardiol. 2014 May-Jun;55(3):227-34.	Organization, structure and data of the Hellenic Heart Registry on Percutaneous Coronary Interventions: a step forward towards outcomes research.
Am J Cardiol. 2014 May 1;113(9):1487-93.	Validation of a new risk score to predict contrast-induced nephropathy after percutaneous coronary intervention.
Int J Cardiol. 2015 Oct 15;197:48-55. doi: 10.1016/j.ijcard.2015.06.019. Epub 2015 Jun 18.	Spot urine albumin to creatinine ratio outperforms novel acute kidney injury biomarkers in patients with acute myocardial infarction.
Circulation. 2019 Apr 23;139(17):2032-2048. doi: 10.1161/CIRCULATIONAHA.118.037166	Lysed Erythrocyte Membranes Promote Vascular Calcification.
J Clin Med. 2019 Jul 9;8(7). pii: E1000. doi: 10.3390/jcm8071000.	Increased Lymphangiogenesis and Lymphangiogenic Growth Factor Expression in Perivascular Adipose Tissue of Patients with Coronary Artery Disease
Int J Mol Sci. 2019 Dec 31;21(1). pii: E282. doi:	Age-Dependent and -Independent Effects of Perivascular Adipose Tissue and Its Paracrine

10.3390/ijms21010282. Cardiorenal Med. 2020;10(3):162-174. doi: 10.1159/000506379. Epub 2020 Apr 14.	Activities during Neointima Formation. Application of 17 Contrast-Induced Acute Kidney Injury Risk Prediction Models.
Tziakas DN, Pavlaki M, Chalikias G, Konstantinides SV, Schäfer K. Letter by Tziakas et al Regarding Article, "Aortic Valve Stenosis: From Basic Mechanisms to Novel Therapeutic Targets". Arterioscler Thromb Vasc Biol. 2020 Jun;40(6):e180-e181. doi: 10.1161/ATVBAHA.120.314456. Epub 2020 May 27. PMID: 32459539.	Letter by Tziakas et al Regarding Article, "Aortic Valve Stenosis: From Basic Mechanisms to Novel Therapeutic Targets"
Chalikias G, Tziakas D. Slow Coronary Flow: Pathophysiology, Clinical Implications, and Therapeutic Management. Angiology. 2021 Oct;72(9):808-818. doi: 10.1177/00033197211004390. Epub 2021 Mar 29. PMID: 33779300.	Slow Coronary Flow: Pathophysiology, Clinical Implications, and Therapeutic Management
Chalikias G, Tziakas D. Angiotensin Receptor Neprilysin Inhibitors-2019 Update. Cardiovasc Drugs Ther. 2020 Oct;34(5):707-722. doi: 10.1007/s10557-020-07015-8. PMID: 32519065.	Angiotensin Receptor Neprilysin Inhibitors-2019 Update